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Clinical Implication of Optical Coherence Tomography-Based 
Neoatherosclerosis
Recent research has indicated neoatherosclerosis (NA), the de novo development of 
atherosclerosis within the neointimal region of the stented segment after coronary stent 
implantation, as a mechanism of late/very late stent thrombosis (VLST) and restenosis. This 
research is based on histologic and intravascular imaging studies. Optical coherence 
tomography (OCT) is an imaging tool that is superior with regard to resolution capacity, 
and can be used to visualize detailed information about distinct morphological 
characteristics of the restenotic tissue. Thus, OCT is a valuable imaging tool for examining 
NA, such as macrophage infiltration, lipid accumulation, in-stent calcification, or 
neointimal rupture. This article discusses the prevalence, predictors, and clinical 
implications of NA that can be observed by OCT.
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INTRODUCTION
Drug-eluting stents (DESs) have markedly reduced in-stent re-
stenosis (ISR) and repeat revascularizations (1,2). However, in 
spite of the use of DESs, percutaneous coronary intervention 
(PCI) is still associated with stent failure and is related to stent 
thrombosis or restenosis (3,4), which in turn may be related to 
fatal clinical events. Thus, it is important to investigate the path-
ological mechanisms of stent failure. Although several factors 
for stent failure have been reported, one of the main mechanisms 
is neoatherosclerosis (NA), i.e., the de novo development of ath-
erosclerosis within the neointimal region (5).
 This article discusses the prevalence, predictors, and clinical 
implications of NA observed by optical coherence tomography 
(OCT).
OCT AND NA
OCT-defined NA
NA is defined as atherosclerotic changes in neointimal tissue. It 
was firstly described in pathologic specimens with bare metal 
stents (BMSs), and also recently reported in DES (5). It is char-
acterized by the presence of clusters of lipid-laden foamy mac-
rophages with or without necrotic core formation and/or calci-
fication within the neointimal tissue of stented segments. His-
tological examination can be used for diagnosis; however, it can 
be difficult to obtain pathologic specimens. Therefore, several 
intra-coronary imaging modalities, including intravascular ul-
trasound (IVUS) and OCT, can be used to evaluate coronary stents, 
particularly the mechanisms of stent failure. Current guidelines 
recommend IVUS or OCT to assess the mechanisms of stent 
failure (6,7). However, compared to IVUS, OCT is preferred over 
IVUS due to the resolution capacity (80–120 vs. 10–20 µm), and 
OCT is better for evaluating neointimal tissue within the stent-
ed segment. OCT can provide detailed information regarding 
restenotic tissue (tissue structure, backscatter, microvessels, and 
composition) (8-10). Therefore, it can be used to visualize dis-
tinct morphological characteristics of NA, such as macrophage 
infiltration, lipid accumulation, in-stent calcification, or neointi-
mal rupture.
 On OCT images, OCT-defined NA is mainly confined to li-
pidic or calcific neointima (11,12). Lipidic neointima is shown 
as diffusely bordered, signal-poor regions with overlying signal-
rich bands. Calcific neointima shows well-delineated, signal-
poor regions with sharp borders (13,14). Fig. 1 presents the li-
pidic and calcific neointima defined by OCT evaluation.
Prevalence and predictors of NA
Several studies used OCT to examine the prevalence and risk 
factors of NA. Table 1 summarizes the prevalence of OCT-based 
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NA. The prevalence varies, according to the stent type, the fol-
low-up duration, and clinical indications. Takano et al. (9) eval-
uated neointimal characteristics after BMS implantation at ear-
ly (< 6 months, n = 20) and late (≥ 5 years, n = 21) phases, us-
Table 1. Prevalence, predictors, and clinical implication of OCT-based NA
Authors Year Subjects
Stent type and  
number of lesions
Duration Prevalence Predictors of NA Clinical implication
Takano et al. 
(9)
2009 Patients with OCT follow-up BMS, n = 21 ≥ 5 yr 67% - -
Kang et al. 
(17)
2011 Symptomatic patients with ISR  
lesions and intimal hyperplasia 
> 50% of stent area
1st and 2nd DES, 
n = 50
Median, 32 mon 90% - Patients with unstable angina  
(vs. stable angina) had more  
unstable OCT findings.
Kim et al. 
(16)
2012 Patients with serial OCT follow-up 
at 9 mon and 2 yr
1st DES, n = 43; 
and 2nd DES, 
n = 33
9 mon; and 2 yr 15%; and 
28%
- -
Yonetsu et al. 
(12)
2012 Patients with OCT follow-up and 
mean neointimal thickness  
> 100 μm 
BMS, n = 73; DES, 
n = 106
Mean, 26.9 mon 47% Stent age, DES vs. BMS, 
smoking, CKD, no use of 
ACEi/ARB
-
Ko et al.  
(31) 
2012 Patients with VLST after DES  
implantation
1st and 2nd DES, 
n = 18
42 mon 22% Time to OCT study -
Lee et al. 
(34)
2013 Patients with OCT follow-up and 
> 50% CSA neointimal stenotic 
lesions
BMS, n = 24; DES, 
n = 128
Median, 70.7 mon 35.5% Stent age, use of first-gen-
eration DES, and hyper-
tension
NA was associated with higher TLR 
(93% vs. 78%) and higher stent 
thrombosis (15% vs. 0%).
Kim et al. 
(26)
2015 Patients with OCT follow-up  
( ≤ 12 mon) and mean neointi-
mal thickness > 100 μm
1st and 2nd DES, 
n = 482
≤ 12 mon, early 
neoatherosclero-
sis
6% Hypertension, pre-stent 
LDL-cholesterol ≥ 130 
mg/dL 
NA was associated with higher clini-
cal symptoms (13% vs. 57%) and 
higher TLR (9% vs. 55%).
Lee et al. 
(18)
2015 Patients with > 50% neointimal 
CSA stenosis
1st DES, n = 101; 
and 2nd DES, 
n = 111
55 mon; and  
12 mon
46%; and 
11%
CKD, LDL-cholesterol at  
follow-up more than 70 
mg/dL, stent age
NA was associated with a higher 
acute coronary syndrome (19.0% 
vs. 3.9%).
Kuroda et al. 
(27) 
2016 Patients with OCT follow-up > 1 
yr after stent implantation
BMS, n = 37; DES, 
n = 277
> 1 yr 17% LDL-cholesterol, CRP levels 
at follow-up
NA was associated with a higher 
MACE (composite of death,  
myocardial infarction, and TLR) 
(37% vs. 9%).
OCT = optical coherence tomography, BMS = bare metal stent, ISR = in-stent restenosis, DES = drug-eluting stent, CKD = chronic kidney disease, ACEi = angiotensin con-
verting enzyme inhibitor, ARB = angiotensin-II receptor blocker, VLST = very late stent thrombosis, CSA = cross-sectional area, NA = neoatherosclerosis, TLR = target-lesion 
revascularization, LDL = low-density lipoprotein, CRP = C-reactive protein, MACE = major adverse cardiovascular event.  
Fig. 1. OCT images of neointima. (A) Lipidic change. (B) Calcific change. Arrows indicate lipid and calcification within neointima, respectively.
OCT = optical coherence tomography.
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ing OCT. Lipid-laden neointima was not observed in the early 
phase, whereas it was observed at the late phase (67% of the pa-
tients). Habara et al. (15) compared neointimal characteristics 
between early ( ≤ 1 year) and late restenosis within BMS ( > 5 
years), and showed that the heterogeneous appearance of neo-
intima was more frequent in late restenosis compared with ear-
ly restenosis (61% vs. 6%). Thus, after BMS implantation, the prev-
alence of NA increased with the stent age. Similarly, after DES 
implantation, stent age is a major predictor of NA. We previous-
ly reported on the serial changes (9 months and 2-year follow-
up after DES implantation) of neointima characteristics in DES-
treated lesions using OCT (16). Lipid-laden neointima (27.6% 
vs. 14.5%, P = 0.009) and thin-cap neoatheroma (13.2% vs. 3.9%, 
P = 0.070) were more frequently detected at 2-year follow-up 
compared with 9 months of follow-up. In addition, the change 
of neointimal morphology from homogeneous to heterogeneous 
or a lipid-laden pattern was observed in 30% of cases. Kang et al. 
(17) investigated 50 patients who presented with stable (n = 30) 
or unstable angina (n = 20) with DES restenosis using OCT, and 
found lipid-containing neointima in 90% of lesions. Twenty-six 
lesions (52%) had thin-cap fibroatheroma (TCFA)-containing 
neointima and 29 lesions (58%) had at least one in-stent neointi-
mal rupture. In addition, when we analyzed a total of 212 DES-
treated patients (second-generation DES, 52.4%) with > 50% 
neointimal cross-sectional area (CSA) stenosis that were retro-
spectively enrolled from the Korean multicenter OCT registry, 
the incidence of NA increased with stent age (18). NA was found 
in 1.6% (1/64) of the lesions identified in less than 1 year. In com-
parison, NA was observed in 73.9% (17/23) of the lesions over 7 
years (18).
 With regard to stent type, DES might be associated with a high-
er risk of NA, compared with BMS, and Yonetsu et al. (12) eval-
uated NA predictors, where all subtypes of DES were found to 
be independent predictors of NA compared with BMS. Similar-
ly, Ali et al. (19) reported that prior DES vs. BMS (odds ratio [OR], 
7.0; P = 0.006) was a predictor of NA. However, among the DES 
cases, second-generation DES was not found to be more pro-
tective against NA compared with the first-generation DES (18). 
Additionally, NA was observed earlier in DES-treated lesions 
compared with BMS-treated lesions based on the results of a 
pathologic study (5). A possible explanation for the higher risk 
of NA with DES vs. BMS could be that the inhibition of neointi-
mal hyperplasia by local drug delivery causes delayed coverage 
and dysfunction of endothelial cells. Although endothelial cells 
could be barriers that prevent lipid infiltration and inflamma-
tory cell migration, incomplete maturation of the regenerated 
endothelium was more frequently observed in DES vs. BMS (20, 
21). Considering these suggested mechanisms, although these 
metallic stents have been related to NA, bioresorbable vascular 
scaffolds could be expected to reduce NA. The recovery of va-
somotion in the scaffolded segment was noted after bioresorb-
able vascular scaffold implantation, and a signal-rich layer sep-
arated the potentially thrombogenic plaque components from 
the lumen; this suggests a favorable long-term healing response 
with potential plaque sealing, which was observed in a recent 
OCT follow-up study (22,23). Furthermore, no cases of necrotic 
core accumulation of adluminal origin were observed (24).
 This study did not evaluate whether the initial OCT findings 
at the index PCI can predict the development of NA at follow-
up OCT, and the presence of unstable underlying lesion mor-
phology was found to be a significant risk factor of NA based on 
autopsy cases (5). Nakazawa et al. (5) reported that stent struts 
embedded in the necrotic core, where the effect of the drug like-
ly persists for a long period of time, potentially causes dysfunc-
tional and/or incompetent endothelium, which can lead to the 
development of NA. Similarly, Tian et al. (25) found that NA was 
more frequently associated with adjacent lipid plaque at follow-
up OCT. Therefore, the plaque character can be determined by 
pre-procedural OCT and can be used as a predictor of NA.
 Although one of the strongest risk factors of NA is a longer 
time interval to follow-up, when we used OCT to evaluate the 
incidence of NA that developed after short post-DES implanta-
tion durations, early NA was also observed in 6.4% of 482 DES-
treated lesions within 12 months after stent implantation (at a 
median post-implantation follow-up of 9.1 months) (26). Inde-
pendent predictors of early NA were hypertension (OR, 3.20; 
P = 0.010) and pre-stent low-density lipoprotein (LDL) choles-
terol ≥ 130 mg/dL at the time of index procedure (OR, 3.89; P =  
0.002). Other clinical predictors of NA are also summarized in 
Table 1. Yonetsu et al. (12) assessed 179 stents (mean duration, 
26.9 months; DES, 59%) and reported OCT-detected NA (lipid-
laden neointimal and/or calcification within the neointima) in 
84 lesions (47%). In this study, independent determinants of 
OCT-detected NA were current smoking, chronic kidney disease 
(CKD), and absence of angiotensin-converting enzyme inhibi-
tors or angiotensin II receptor blockade usage. We also analyzed 
the restenotic lesions with first-generation DES (n = 101) and 
second-generation DES (n = 111), and found CKD and LDL cho-
lesterol at follow-up with values that were more than 70 mg/dL, 
which were both independent predictors of NA. From the Kobe 
University Hospital OCT registry (175 patients, 314 lesions), Ku-
roda et al. (27) found that C-reactive protein (CRP) level (OR, 
1.022; P = 0.001) and LDL cholesterol (OR, 1.022; P = 0.008) at 
follow-up were independently associated with the presence of 
NA. Although the exact mechanisms need to be investigated 
further, these results additionally support the postulated mech-
anism of NA; that is to say, oxidative stress and inflammation 
lead to atherosclerotic changes inside neointima (12,26). These 
findings support the importance of secondary prevention after 
stent implantation.
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CLINICAL IMPLICATION OF NA: ISR AND STENT 
THROMBOSIS
Recent studies with OCT suggest that NA may play an impor-
tant role in late stent failure, both for ISR and stent thrombosis. 
Vergallo et al. (28) reported that the mean neointimal thickness 
was independently associated with the presence of NA (OR, 2.53; 
P < 0.001). This association was independent from stent type 
and time from implantation, suggesting a possible pathologic 
link between the 2 processes, neointimal thickness and NA. Sim-
ilarly, after DES implantation, late ISR and very late ISR were 
associated with NA, suggesting that these could contribute to 
the late catch-up phenomenon after DES (29). Additionally, re-
cent OCT findings in patients with late and very late stent throm-
bosis (VLST) reported a high prevalence of plaque rupture and 
impaired healing (30-33). According to a prospective multicenter 
registry, ruptured neoatherosclerotic lesions were more frequent 
with BMS than with DES (36% vs. 14%, P = 0.005), and late/VLST 
were mainly related to malapposition (31%) and NA (28%) (32). 
Therefore, NA may contribute to both ISR and stent thrombo-
sis. Neoatherosclerotic OCT images in patients that presented 
with ISR and stent thrombosis are shown in Fig. 2.
 Patients with NA had higher chances of symptoms or need of 
repeat vascularization (Table 1) (34). We evaluated the neointi-
mal characteristics of 152 lesions (128 DESs and 24 BMSs) with 
> 50% CSA neointimal stenosis. NA was observed in 54 lesions 
(35.5%, 35 DESs and 19 BMSs), and patients with NA vs. with-
out NA had a higher rate of target lesion revascularization (92.6% 
vs. 77.6%, P = 0.018) and stent thrombosis (14.8% vs. 0%, P < 0.001) 
(34). Similarly, from the Korean multicenter OCT registry, pati-
ents with NA showed a higher rate of acute coronary syndrome 
at follow-up OCT (19.0% vs. 3.9%, P = 0.001) (18). In addition, 
based on data from the Kobe University Hospital OCT registry, 
the incidence of major adverse cardiovascular events (MACEs; 
e.g., composite of death, myocardial infarction, and target-lesion 
revascularization [TLR]) was significantly higher in patients with 
NA vs. those without NA (36.9% vs. 9.3%, P < 0.001). This was 
mainly driven by an increase in the rate of cardiac death (6.5% 
vs. 0%, P = 0.017) and TLR (30.4% vs. 7.7%, P < 0.001). Moreover, 
the incidence of stent thrombosis (definite/probable) was sig-
nificantly higher in patients with NA (6.5% vs. 0%, P = 0.017) (27). 
Patients with early NA (within 12 months after stent implanta-
tion) also had a higher incidence of clinical symptoms (13% vs. 
57%, P < 0.001) and had undergone a higher frequency of TLR 
(9% vs. 55%, P < 0.001) at the time of OCT follow-up (26).
 Clinical presentation of NA can vary from asymptomatic or 
stable angina to life-threatening acute coronary syndrome be-
cause of stent thrombosis. Compared to patients with stable an-
gina, patients with unstable angina show higher incidences of 
unstable OCT findings, including TCFA-containing neointima, 
neointima rupture, and thrombus (P = 0.027) (17). OCT-defined 
rupture of lipidic neointima was observed in patients with VLST 
(31).
 In addition, when treating ISR, the neointimal characteristic 
Fig. 2. OCT images of neoatherosclerotic neointima in patients with ISR (A) and stent thrombosis (B). (A) Lumen is narrow for NA in a patient with ISR. (B) Disrupted neointima 
(arrows) with thrombi (arrowheads) is observed in a patient with stent thrombosis.
ISR = in-stent restenosis, NA = neoatherosclerosis.
A B
Hong S-J, et al. • OCT-Based Neoatherosclerosis
1060  http://jkms.org https://doi.org/10.3346/jkms.2017.32.7.1056
of ISR lesions, particularly NA, could impact the periprocedural 
myocardial injury. We analyzed a total of 125 patients with ISR 
lesions (35). Post-PCI creatine kinase-myocardial band (CK-MB) 
elevation was observed in 20 (16.0%) patients, and multivariate 
analysis revealed that the maximum length of segments with NA 
(OR, 1.463; P = 0.011) and TCFA (OR, 14.328; P = 0.041) were 
independent predictors for post-PCI CK-MB elevation. Thus, 
NA may underlie the vulnerability of neointima to PCI, with a 
distal microembolization of neointimal debris.
 Although routine OCT examination is not necessary for all 
patients who undergo follow-up angiography, the data from 
these studies indicates that OCT examination can be valuable 
for patients with symptoms and angiographically-significant 
stenosis. For these patients, OCT examination can determine 
the presence of NA for future risk stratification and can be use-
ful for evaluating the mechanism of stent failure for targeted 
therapeutic approaches. Additional studies are needed to de-
termine whether these results can be translated to clinical im-
provements.
CONCLUSION 
Recent evidence has indicated that NA is a considerable mech-
anism of late/VLST and restenosis. In addition, it is an impor-
tant substrate for future adverse events. Thus, detection of NA 
by OCT and identification of morphological characteristics, in-
cluding in-stent lipidic or calcific neointima, is helpful for pre-
dicting and preventing greater future adverse events.
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